Propionic Acid in Multiple Sclerosis - Trial NCT06402487
Access comprehensive clinical trial information for NCT06402487 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Salzburger Landeskliniken and is currently Enrolling by invitation. The study focuses on Multiple Sclerosis. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Salzburger Landeskliniken
Timeline & Enrollment
Phase 2/3
May 01, 2024
Oct 15, 2024
Primary Outcome
Serum neurofilament light chain (NfL),Serum glial fibrillary acid protein (GFAP)
Summary
The purpose of this study is to demonstrate the superiority of propionic acid over placebo as
 add on treatment in multiple sclerosis (MS).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06402487
Non-Device Trial